Research Use Only · Dosing data compiled from published literature · Not for human or veterinary use

Tirzepatide Dosage & Reconstitution

Dual GIP/GLP-1 receptor agonist. Work out exactly what to draw for your own mix, see the doses used in research, and follow a week-by-week plan. Evidence tier: clinical.

1Set Up Your Mix

13.333 mg/mL · 13333 mcg/mL

Your Answer — Tirzepatide

20 mg in 1.5 mL
18.8Draw To This Line
0.188That's This Many mL
8Doses In The Vial
0102030405060708090100 U-100 syringe · 1 mL · 100 units draw to 18.8
20 mg ÷ 1.5 mL = 13.333 mg/mL  →  2.5 mg ÷ 13.333 mg/mL = 0.188 mL  →  × 100 = 18.8 units
Looks good. Draw to 18.8 units on a 1 mL syringe. That is an easy amount to measure, and this vial gives you 8 doses.
When to dose
Time of dayAny time of day. Weekly compounds should be kept to the same day each week.
FoodWith or without food — it makes no meaningful difference.

These are long-acting and reach steady state over weeks, so a single day’s timing has little effect. Consistency matters more than the hour.

2Week-By-Week Plan — Tirzepatide

Approved-label escalation
WhenDoseHow OftenHow Many mLDraw ToNumber Of DosesPeptide Used
Weeks 1–4 2.5 mg once weekly 0.188 mL 18.8 u 4 10 mg
Weeks 5–8 5 mg once weekly 0.375 mL 37.5 u 4 20 mg
Weeks 9–12 7.5 mg once weekly 0.563 mL 56.3 u 4 30 mg
Weeks 13–16 10 mg once weekly 0.75 mL 75 u 4 40 mg
Weeks 17–20 12.5 mg once weekly 0.938 mL 93.8 u 4 50 mg
Week 21 onward
per 4 weeks from here on
15 mg once weekly 1.125 mL 112.5 u ⚠ 4 60 mg
Time until the top dose
20 weeks
Peptide used getting there
150 mg
Vials you'll need
8 × 20 mg
Once you're at the top dose
60 mg / 4 wk · 3 vials
Where this plan came from
A published dosing schedule
Where this came from: SURMOUNT-1 protocol and the approved label — 2.5 mg start, one step every four weeks. 5 mg, 10 mg and 15 mg are all recognised maintenance doses. Escalation stops at the assigned maintenance dose rather than always running to 15 mg.

3Common Doses — Tirzepatide

worked out for your mix
LevelDoseHow OftenHow Many mLDraw ToDoses In Vial
Initiation (wk 1–4) 2.5 mg once weekly 0.188 mL 18.8 u 8 doses
Step 2 5 mg once weekly 0.375 mL 37.5 u 4 doses
Step 3 7.5 mg once weekly 0.563 mL 56.3 u 2 doses
Step 4 10 mg once weekly 0.75 mL 75 u 2 doses
Trial maximum 15 mg once weekly 1.125 mL 112.5 u ⚠ 1 doses
Please read this. These numbers come from published research. They are here as reference, not as instructions. A lot of them come from lab studies rather than studies in people, and some of these peptides have never been given to a person at all.

About Tirzepatide

Metabolic / Incretin
Also known as
Dual GIP/GLP-1 receptor agonist
Class
Metabolic / Incretin
Route
Subcutaneous
Half-life
~5 days
Evidence tier
Clinical

A dual incretin agonist. SURMOUNT-1 established the 5/10/15 mg maintenance arms with a four-week-per-step escalation from 2.5 mg.

Buy Tirzepatide

Common Questions — Tirzepatide

How much bacteriostatic water do I add to a 20 mg vial of Tirzepatide?

Adding 1.5 mL of bacteriostatic water to a 20 mg vial gives 13.3 mg/mL. That is the mix every number on this page is worked out from — change the water figure in the calculator and all the draw amounts update.

What dose of Tirzepatide is used in research?

Published and reported figures for Tirzepatide run from 2.5 mg to 15 mg, typically once weekly.5 mg to 15 mg, typically once weekly.5 mg to 15 mg, typically once weekly. This site lists each figure with the source it came from rather than giving a single recommended number.

How many units on the syringe is a 2.5 mg dose of Tirzepatide?

At 13.3 mg/mL, a 2.5 mg dose is 18.8 units on a 1 mL U-100 insulin syringe. One vial at that mix gives about 8 doses.

How strong is the evidence behind these Tirzepatide doses?

Tirzepatide is graded clinical. Human trial or approved-label dosing has been published for this compound. We grade every compound on this site so you can weigh the numbers accordingly — the full method is on our editorial policy page.

Is there a Tirzepatide titration schedule?

Yes — Approved-label escalation. The week-by-week table on this page converts each step into the exact amount to draw for your mix.

Where These Numbers Come From

Clinical — Human trial or approved-label dosing published
Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1) Jastreboff AM, et al. New England Journal of Medicine, 2022
Pivotal obesity trial; source of the 5/10/15 mg arms and escalation schedule.
Find on PubMed ↗
Tirzepatide versus semaglutide once weekly in type 2 diabetes (SURPASS-2) Frías JP, et al. New England Journal of Medicine, 2021
Head-to-head dose-response against semaglutide.
Find on PubMed ↗

Newest Studies —

Not reviewed by us. This list is pulled straight from Europe PMC as papers are published. Nobody has checked whether these are any good, or whether they change anything above. The dose numbers on this page only ever change after a person reviews the evidence.

Need this on one page to print, screenshot or send?

Make a dose card →

Other metabolic / incretin peptides

Compounds in the same class, or browse the full catalogue.

5-Amino-1MQ

A small-molecule NNMT inhibitor rather than a true peptide. Research data show reduced adiposity in diet-induced obesity models. D…

All 72 peptides

Every compound compared in one table: dose range, how often, half-life and evidence tier.